PV Patient Profile | Jakafi®/Jakafi XR™ (ruxolitinib) Skip to main content
Person seated beside a counter with beverage equipment in the background

Is Arthur at risk of thrombosis while on HU and PBT?

This profile represents a hypothetical patient.

This profile represents a hypothetical patient.

icon PV Up Arrow

The risk of thrombosis increased based on risk factors such as1-3:

  • Hct ≥45% 
  • ≥3 PBTs/year
  •  WBC >11 × 109/L

Evaluating Arthur

59-year-old4 widowed microbrewer

  • Experienced a deep vein thrombosis 5 years ago4 
  • Diagnosed with PV 2.5 years ago4
  • Initially treated with HU 1 g/day3

What Changed WITH ARTHUR

icon PV Up Arrow

Lab results4

Elevated blood counts

  • Hct: 46.3%; WBC: 12 × 109/L

Treatment

  • HU titrated to 1.5 g/day, the maximum tolerated dose, 6 months ago3
  • Received 2 PBTs recently4
  • Hct elevated again at current visit4

Treatment

  • HU titrated to 1.5 g/day, the maximum tolerated dose, 6 months ago3
  • Received 2 PBTs recently4
  • Hct elevated again at current visit4

Are Arthur’s blood counts really controlled while on HU and PBT, or is his risk of thrombosis increasing?1-4

How common is HU failure?

In a retrospective, real-world study of patients with PV who received pharmacologic cytoreductive treatment,*

The majority of patients still had a suboptimal response† to HU at 6 months5

Blood Count Control Among Patients With PV During Pharmacologic Cytoreductive Treatment at 6 Months (n=2015)5

Bar chart showing blood count control among patients with polycythemia vera during cytoreductive treatment at 5 months

Characteristics, blood counts, treatments, and clinical outcomes of 5871 patients with polycythemia vera treated in US community practices. Lyons RM, Aguilar KM, Sudharshan L, et al. Current Medical Research and Opinion. © 2025 Informa UK Limited. Reprinted by permission of the publisher Informa UK Limited trading as Taylor & Francis Ltd, http://www.tandfonline.com.

*A retrospective observational study of 5871 adult patients with a documented diagnosis of PV in the single-source iKnowMed electronic health record database from US Oncology Network and non-Network clinics. 2257 of these patients received pharmacologic cytoreductive treatment and were evaluable for blood count control.5

†Suboptimal response to HU was defined as meeting ≥1 of the following criteria after ≥3 months of treatment: (1) Hct >45%, (2) WBC count >10 ⨯ 109/L, and/or (3) platelet count >400 ⨯ 109/L.5

90%

What happens when Hct ≥45% and WBC count >11 × 109/L?

Hematocrit between 45% and 50% =
4x GREATER RISK OF THROMBOSIS AND CV DEATH1

CYTO-PV study1‡

Kaplan-Meier curve showing the probability of remaining event-free in the CYTO-PV study

Kaplan-Meier curves for primary composite endpoint.

From The New England Journal of Medicine, Marchioli R, Finazzi G, Specchia G, et al; for the CYTO-PV Collaborative Group, Cardiovascular events and intensity of treatment in polycythemia vera, 368(1):22-33. © 2013 Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society.

‡In the CYTO-PV study of 365 adult patients with PV treated with PBT, HU, or both, patients were randomized to 1 of 2 groups: the low-Hct group (n=182; with more intensive therapy to maintain a target Hct level <45%) or the high-Hct group (n=183; with less intensive therapy to maintain a target Hct level of 45% to 50%). Baseline characteristics were balanced between the groups. Approximately 50% of patients had received an initial diagnosis of PV within 2 years prior to randomization. Sixty-seven percent of patients (n=245) were at high risk because they were ≥65 years of age or had experienced previous thrombosis. The composite primary endpoint was the time until CV death or major thrombosis.1

Elevated WBC count >11 x 109/L =
4x greater risk of thrombosis vs WBC count <7 x 109/L2

Additional analysis from the CYTO-PV study2

Bar chart showing time-dependent multivariable analysis of major thrombosis risk by WBC count in the CYTO-PV study

aAdjusted for age, gender, CV risk factors, previous thrombosis, and Hct levels.2

  • In this analysis, there was a trend for increased risk of thrombosis with WBC count >7 × 109/L (ie, HR >1) that became statistically significant in patients with WBC counts >11 × 109/L2 
  • These results are consistent with other literature that suggests leukocytosis may increase the risk of thrombosis6,7

≥3 phlebotomies per year

increased the risk of thrombosis in a real-world study of 533 HU-treated PV patients3§

§A retrospective analysis of a real-world study of 1353 patients with PV. Of these patients, 533 who were treated with HU had available data regarding hematologic values, PBT requirements, and HU dose. Hematocrit levels, number of PBTs, and dose of HU were assessed at months 6, 12, 18, 24, 36, 48, and 60 of HU therapy. The requirement of PBT in each patient was calculated as the total number of PBTs divided by time of follow-up and expressed as the number of PBTs per year.3

NCCN Guidelines® recommend

Actively monitoring patients’ response and signs/symptoms of disease progression8||

Potential indications for change of cytoreductive therapy for patients with symptomatic low-risk PV, or high-risk PV with inadequate response or loss of response:

  • Intolerance or resistance to HU or interferons
  • Disease-related symptoms (eg, pruritus, night sweats, fatigue)
  • New thrombosis or disease-related major bleeding
  • Progressive thrombocytosis and/or leukocytosis
  • Frequent phlebotomy or intolerant of phlebotomy
  • Splenomegaly

||Every 3 to 6 months or more frequently as clinically indicated.8

CI=confidence interval; CV=cardiovascular; CYTO-PV=Cytoreductive Therapy in Polycythemia Vera; Hct=hematocrit; HR=hazard ratio; HU=hydroxyurea; NCCN=National Comprehensive Cancer Network® (NCCN®); PBT=phlebotomy; PV=polycythemia vera; TFS=thrombosis-free survival; WBC=white blood cell.

References: 1. Marchioli R, Finazzi G, Specchia G, et al; for CYTO-PV Collaborative Group. Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med. 2013;368(1):22-23. 2. Barbui T, Masciulli A, Marfisi MR, et al. White blood cell counts and thrombosis in polycythemia vera: a subanalysis of the CYTO-PV study. Blood. 2015;126(4):560-561. 3. Alvarez-Larrán A, Pérez-Encinas M, Ferrer-Marín F, et al. Risk of thrombosis according to need of phlebotomies in patients with polycythemia vera treated with hydroxyurea. Haematologica. 2017;102(1):103-109. 4. Vannucchi AM, Kiladjian JJ, Griesshammer M, et al. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med. 2015;372(5):426-435. Supplementary appendix available at: https://www.nejm.org/doi/suppl/10.1056/NEJMoa1409002/suppl_file/nejmoa1409002_appendix.pdf. 5. Lyons RM, Aguilar KM, Sudharshan L, et al. Characteristics, blood counts, treatments, and clinical outcomes of 5871 patients with polycythemia vera treated in US community practices. Curr Med Res Opin. 2025;41(1):43-51. 6. Gangat N, Strand J, Li C-Y, Wu W, Pardanani A, Tefferi A. Leucocytosis in polycythemia vera predicts both inferior survival and leukaemic transformation. Br J Haematol. 2007;138(3):354-358. 7. Grunwald MR, Kuter DJ, Altomare I, et al. Treatment patterns and blood counts in patients with polycythemia vera treated with hydroxyurea in the United States: an analysis from the REVEAL study. Clin Lymphoma Myeloma Leuk. 2020;20(4):219-225. 8. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Myeloproliferative Neoplasms V.3.2026. © National Comprehensive Cancer Network, Inc. 2026. All rights reserved. Accessed September 20, 2026. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way. 

 
 

IMPORTANT SAFETY INFORMATION

Warnings and Precautions

Thrombocytopenia, Anemia and Neutropenia

  • JAKAFI®/JAKAFI XR™ (ruxolitinib) can cause dose‑related effects of thrombocytopenia, anemia and neutropenia. Perform a pre‑treatment complete blood count (CBC) and monitor CBCs every 2 to 4 weeks until doses are stabilized, and then as clinically indicated.
  • Manage thrombocytopenia by reducing the dose or temporarily interrupting JAKAFI/JAKAFI XR. Platelet transfusions may be necessary.
  • Patients developing anemia may require blood transfusions and/or dose modifications of JAKAFI/JAKAFI XR.
  • Severe neutropenia (ANC <0.5 × 109/L) was generally reversible by withholding JAKAFI/JAKAFI XR until recovery.

INDICATIONS AND USAGE

JAKAFI®/JAKAFI XR™ (ruxolitinib) is for treatment of intermediate or high‑risk myelofibrosis (MF), including primary MF, post–polycythemia vera MF and post–essential thrombocythemia MF in adults.

JAKAFI/JAKAFI XR is for treatment of polycythemia vera (PV) in adults who have had an inadequate response to or are intolerant of hydroxyurea.

JAKAFI/JAKAFI XR is for treatment of steroid‑refractory acute graft‑versus‑host disease (aGVHD) in adult and pediatric patients 12 years and older.

JAKAFI/JAKAFI XR is for treatment of chronic graft‑versus‑host disease (cGVHD) after failure of one or two lines of systemic therapy in adult and pediatric patients 12 years and older.

Risk of Infection

  • Serious bacterial, mycobacterial, fungal and viral infections have occurred. Delay starting JAKAFI/JAKAFI XR until active serious infections have resolved. Observe patients receiving JAKAFI/JAKAFI XR for signs and symptoms of infection and manage promptly.

Tuberculosis

  • Tuberculosis (TB) infection with JAKAFI/JAKAFI XR has been reported. Observe patients taking JAKAFI/JAKAFI XR for signs and symptoms of active TB and manage promptly. Prior to initiating, evaluate patients for TB risk factors and test those at higher risk for latent infection. Consult a physician with expertise in the treatment of TB before starting in patients with evidence of active or latent TB. Continuation during treatment of active TB should be based on the overall risk‑benefit determination.

Progressive Multifocal Leukoencephalopathy

  • Progressive multifocal leukoencephalopathy (PML) has occurred with JAKAFI/JAKAFI XR treatment. If PML is suspected, stop JAKAFI/JAKAFI XR and evaluate.

Herpes Zoster and Herpes Simplex

  • Herpes zoster infection, reactivation and/or dissemination has been reported in patients receiving JAKAFI/JAKAFI XR. Advise patients about early signs and symptoms of herpes zoster and seek treatment. Monitor patients for the development of herpes simplex infections. If a patient develops evidence of dissemination of herpes simplex, consider interrupting treatment.

Hepatitis B

  • Increases in hepatitis B viral load with or without associated elevations in alanine aminotransferase and aspartate aminotransferase have been reported in patients with chronic hepatitis B virus (HBV) infections.

Symptom Exacerbation Following Interruption or Discontinuation of Treatment

  • When discontinuing JAK‑Inhibitors, including JAKAFI/JAKAFI XR, myeloproliferative neoplasm‑related signs and symptoms may flare. After discontinuation, some patients with myelofibrosis have experienced fever, respiratory distress, hypotension, disseminated intravascular coagulation (DIC), or multi‑organ failure. If any of these occur after discontinuation or while tapering JAKAFI/JAKAFI XR, evaluate and treat any intercurrent illness and consider restarting or increasing the dose. Instruct patients not to interrupt or discontinue JAKAFI/JAKAFI XR without consulting their physician. When discontinuing or interrupting JAKAFI/JAKAFI XR for reasons other than life‑threatening toxicities, consider gradual tapering rather than abrupt discontinuation.

Non‑Melanoma Skin Cancer (NMSC)

  • NMSC including basal cell, squamous cell, and Merkel cell carcinoma have occurred. Perform periodic skin examinations.

Lipid Elevations

  • Treatment with JAKAFI/JAKAFI XR has been associated with increases in total cholesterol, low‑density lipoprotein cholesterol, and triglycerides. Assess lipid parameters 8‑12 weeks after initiation.

Major Adverse Cardiovascular Events (MACE)

  • Another JAK‑inhibitor has increased the risk of major adverse cardiovascular events (MACE), including cardiovascular death, myocardial infarction, and stroke (compared to those treated with TNF blockers), in patients with rheumatoid arthritis, a condition for which JAKAFI/JAKAFI XR is not indicated. Consider the benefits and risks for the individual patient prior to initiating or continuing therapy, particularly in patients who are current or past smokers and patients with other cardiovascular risk factors. Patients should be informed about the symptoms of serious cardiovascular events and the steps to take if they occur.

Thrombosis

  • Another JAK‑inhibitor has increased the risk of thrombosis, including deep venous thrombosis (DVT), pulmonary embolism (PE), and arterial thrombosis (compared to those treated with TNF blockers), in patients with rheumatoid arthritis, a condition for which JAKAFI/JAKAFI XR is not indicated. In patients with myelofibrosis (MF) and polycythemia vera (PV), the rates of thromboembolic events were similar in JAKAFI/JAKAFI XR and control treated patients. Patients with symptoms of thrombosis should be promptly evaluated and treated appropriately.

Secondary Malignancies

  • Another JAK‑inhibitor has increased the risk of lymphoma and other malignancies, excluding NMSC (compared to those treated with TNF blockers), in patients with rheumatoid arthritis, a condition for which JAKAFI/JAKAFI XR is not indicated. Patients who are current or past smokers are at additional increased risk.

Adverse Reactions

  • In myelofibrosis, the most common hematologic adverse reactions (incidence >20%) were thrombocytopenia and anemia. The most common nonhematologic adverse reactions (incidence ≥15%) were bruising, dizziness and headache.
  • In polycythemia vera, the most common hematologic adverse reactions (incidence >20%) were anemia and thrombocytopenia. The most common nonhematologic adverse reactions (incidence ≥15%) were diarrhea and dizziness.
  • In acute graft‑versus‑host disease, the most common hematologic adverse reactions (incidence >50%) were anemia, thrombocytopenia and neutropenia. The most common nonhematologic adverse reactions (incidence >50%) were infections (pathogen not specified) and edema.
  • In chronic graft‑versus‑host disease, the most common hematologic adverse reactions (incidence >35%) were anemia and thrombocytopenia. The most common nonhematologic adverse reactions (incidence ≥20%) were infections (pathogen not specified) and viral infections.

Drug Interactions

  • Avoid concomitant use with fluconazole doses greater than 200 mg. Dose modifications may be required when administering fluconazole doses of 200 mg or less, or with strong CYP3A4 inhibitors, or in patients with renal or hepatic impairment. Patients should be closely monitored and the dose titrated based on safety and efficacy.

Pregnancy

  • Use during pregnancy is not recommended and should only be used if the potential benefit justifies the potential risk to the fetus. Women taking JAKAFI/JAKAFI XR should not breastfeed during treatment and for 2 weeks after the final dose.

Please see Full Prescribing Information for JAKAFI/JAKAFI XR.